Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096843 | 0.91 | HIF1A (0.41) | CYP2C19CYP2C9CYP3A4CYP2D6PPARG | |
| SCHEMBL12096905 | 0.84 | PPARG (0.50) | PTGER1CYP2C19CYP2C9PPARGPPARA | |
| SCHEMBL28807365 | 0.84 | PTGER1 (0.40) | PTGER1CYP2C19CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL12096810 | 0.82 | POLB (0.41) | CYP2C19CYP2C9CYP3A4CYP2D6PPARG | |
| SCHEMBL12097011 | 0.82 | CYP3A4 (0.39) | CYP2C19CYP2C9CYP3A4CYP2D6PPARG | |
| SCHEMBL12096717 | 0.82 | MRGPRX4 (0.43) | CYP2C19CYP2C9CYP3A4CYP2D6PPARG | |
| SCHEMBL14054162 | 0.79 | TP53 (0.38) | PTGER1PPARGPPARAPPARDTP53 | |
| SCHEMBL12097004 | 0.77 | CYP3A4 (0.40) | CYP2C19CYP2C9CYP3A4CYP2D6PPARG | |
| SCHEMBL12096587 | 0.76 | PPARG (0.47) | PPARGPPARAPPARDMAPT | |
| SCHEMBL28947331 | 0.76 | MAPT (0.36) | PTGER1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | claimed |
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | PTGER1 535/4885CYP2C19 2424/4885CYP2C9 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.